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Guaraná  (Paullinia  cupana  Kunth,  Sapindaceae)  is well  known  for  its dietary  and  pharmaceutical  potential,
and the semipuriﬁed  extract  of  guaraná  shows  antidepressant  and  panicolytic  effects.  However,  the  low
solubility,  bioavailability  and  stability  of  the  semipuriﬁed  extract  limit  its use  as a  component  of  phar-
maceutical  agents.  Delivery  of the  semipuriﬁed  extract  in a  microparticle  form  could  help  to  optimize
its  stability.  In this  study,  microparticles  containing  semipuriﬁed  extract  of  guaraná  were  obtained  by
the spray-drying  technique,  using  a  combination  of  maltodextrin  and gum  arabic.  The  raw  materials  and
microparticles  produced  were  characterized  by particle  size  analysis,  differential  scanning  calorimetry,
thermogravimetric  analysis,  and  scanning  electron  microscopy.  The  drug  content  and  antioxidant  capac-
ity were  also  evaluated.  In  vitro  dissolution  tests  using  ﬂow  cell  dissolution  apparatus,  were  carried  out  to
investigate  the inﬂuence  of  formulation  parameters  on the  release  of  semipuriﬁed  extract  of guaraná  from
the microparticles.  The  spray-drying  technique  and the  processing  conditions  selected  gave  satisfactory
encapsulation  efﬁciency  (80–110%)  and  product  yield  (55–60%).  The  mean  diameter  of  microparticles  was
around  4.5  m. The  DPPH  radical  scavenging  capacity  demonstrated  that  microparticles  can  protect  the
semipuriﬁed  extract  of  guaraná  from  the  effect  of high  temperatures  during  the  process  maintained  the
antioxidant  capacity.  Differential  scanning  calorimetry  results  indicated  an  interaction  between  semipu-
riﬁed  extract  of  guaraná  and  gum  arabic:  maltodextrin  in  the  microparticles,  and  thermogravimetric
analysis  indicate  that  the  proﬁle  curves  of  the  microparticles  are  similar  to  the  adjuvants  used  in drying,
probably  due  to  the  higher  proportion  of  adjuvants  compared  to  semipuriﬁed  extract  of  guaraná.  In vitro
dissolution  tests  demonstrate  that  all  formulations  complete  dissolution  within  60  min. Microencapsula-
tion  improved  the  technological  characteristics  of  the  powders  and  preserved  the  antioxidant  properties.
The  study  demonstrated  the  feasibility  of  producing  these  microparticles  for a  one-step  process  using
spray  drying.  The  composition  of  each  formulation  inﬂuenced  the  physical  and  chemical  characteristics.
This  spray-drying  technique  can  be used  as an efﬁcient  and  economical  approach  to  produce  semipuriﬁed
extract  of guaraná  microparticles.
©  2015  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Phytotherapy is making a recognized and effective contribution
o public health, and the development of new herbal medicines
n intermediate and ﬁnal pharmaceutical forms is a contribution to
his trend (Klein et al., 2009). The seeds of guaraná – Paullinia cupana
unth, Sapindaceae, a Brazilian plant, are used in folk medicine as stimulant of the central nervous system, in cases of physical and
ental stress, and as an antidiarrheic, diuretic, and antineuralgic
Henman, 1982; Yamaguti-Sasaki et al., 2007). The seeds contain
∗ Corresponding author.
E-mail: mello@uem.br (J.C.P. de Mello).
http://dx.doi.org/10.1016/j.bjp.2015.03.010
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editorahigh amounts of methylxanthines including caffeine, theophylline,
and theobromin, besides saponins, and polyphenols, especially tan-
nins (Henman, 1982). Chemical assay of a semipuriﬁed extract of
guaraná (EPA) showed the presence of caffeine, epicatechin, cate-
chin, ent-epicatechin, and procyanidins B1, B2, B3, B4, A2, and C1
(Ushirobira et al., 2007; Yamaguti-Sasaki et al., 2007). The antide-
pressant effect has been evaluated with promising results and with
a beneﬁcial effect on cognition, without altering locomotor activ-
ity; the EPA also shows a panicolytic effect (at a dose of 8 mg  kg−1)
(Audi and Mello, 2000; Audi et al., 2010; Otobone et al., 2005, 2007;
Roncon et al., 2011). Low toxicity (Espinola et al., 1997; Mattei et al.,
1998; Otobone et al., 2005, 2007), action as a chemoprophylac-
tic in carcinogenesis (Espinola et al., 1997), and important activity
against Streptococcus mutans (Yamaguti-Sasaki et al., 2007) have
also been demonstrated.
 Ltda. All rights reserved.
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Table 1
Factors, the proportion of GA:MD in the mixed wall material (X1), and total solid
content on total dispersion (X2), and levels of microencapsulation experiment to
optimize the conditions.
Level Factor
X1 (GA:MD) X2 (%, w w−1)
1 30:70 10T. Klein et al. / Revista Brasileira 
The demonstrated antidepressant effect of the EPA on ani-
als may  result from the condensed tannins, which can cross
he blood–brain barrier and affect the central nervous system
Fukumasu et al., 2006; Johnston and Beart, 2004; Otobone et al.,
005, 2007; Ushirobira et al., 2007). The EPA caused no toxicity in
ats at the dose of 30 mg  kg−1 (Antonelli-Ushirobira et al., 2010).
he high potential for using guaraná in a wide range of medicinal
pplications justiﬁes the interest in the development of a pharma-
eutical dosage form.
However, polyphenols are easily degradable by environmen-
al factors such as light, temperature and the presence of oxygen.
he technology of microencapsulation can stabilize these labile
ompounds and extend their shelf life. From an industrial per-
pective, microencapsulated powders are easy to handle and to
se in food and pharmaceutical processing, and maintain their
nitial polyphenol content and bioactivity, increase solubility, and
aintain safety in case of prolonged storage. Microencapsulated
ystems are stable because the coating material provides physi-
al protection and forms a barrier to oxygen and small molecules
Manach et al., 2005; Sansone et al., 2011). Among the meth-
ds for preparing microparticles, the spray-drying technique is
idely used in the pharmaceutical and biochemical ﬁelds, and
n the food industry due to the wide availability of equipment
nd ease of use at an industrial scale (Bruschi et al., 2003). It
s also a mild “one-step” processing operation to move from
 liquid form to a powdered product. Since the rapid solvent
vaporation keeps the droplet temperature far below the tem-
erature of the drying air, spraydrying is strongly recommended
or heat-sensitive materials such as polyphenols (Sansone et al.,
011).
Therefore, considering that EPA contains some labile chemical
ompounds, microencapsulation can increase its stability. The aim
f the present study was to develop and characterize microparti-
les containing EPA, obtained by the spray-drying technique. The
nﬂuence of formulation parameters on the yield of the process
nd on microparticle properties such as morphology, size, ther-
al  behavior, and dissolution/release rate was investigated. The
icroparticles were also evaluated in terms of both EPA content
nd antioxidant capacity.
aterials and methods
aterials
Gum arabic (Synth), maltodextrin (Sigma–Aldrich), methanol
J.T. Baker, HPLC grade), acetonitrile (J.T. Baker, HPLC grade), triﬂu-
roacetic acid (TFA) (J.T. Baker) and ultrapuriﬁed water obtained
rom Milli-Q (Millipore) apparatus were used.
reparation of the EPA semipuriﬁed extract
Samples of guaraná seeds (Paullinia cupana Kunth, Sapin-
aceae) obtained in the municipality of Alta Floresta, state of
ato Grosso, Brazil, were used to prepare the acetone:water
70:30, v v−1) 10% extractive solution (ES), by turbo extrac-
ion (Ultra-Turrax UTC115KT, Ika Works, Wilmington, NC, USA).
he organic solvent was removed in a rotary evaporator under
educed pressure, and the remaining material was  lyophilized
EBPC; Audi and Mello, 2000). The EBPC (crude extract) was
artitioned with ethyl acetate, resulting in an ethyl-acetate frac-
ion (EPA) (Audi and Mello, 2000; Antonelli-Ushirobira et al.,
010). A voucher plant specimen (#HUEM9065) was deposited
t the Herbarium of Universidade Estadual de Maringá, and
he species was identiﬁed by Prof. Dr. Cássia Mônica Sakuragui
UFRJ).2  40:60 20
3  50:50 30
Preparation of EPA microparticles
Dispersions of EPA/gum arabic/maltodextrin (EPA/GA/MD) in
different proportions (Table 1), as a suspension, were spray-dried
using a mini spray dryer (Büchi B-191, Flawil, Switzerland). The
inlet temperature was 190 ◦C, aspiration 80%, pressure established
2 Bar, and pump% of 6%. The outlet temperature was 120–130 ◦C.
A mixture of GA and MD  was  selected as the microencapsulation
wall material. A series of experiments was designed, to optimize
the processing conditions (Zhang et al., 2007). The main factors
selected were (1) the proportion of GA:MD in the wall material (X1),
and (2) total solid content on total dispersion before spray drying
(X2). Details of the experiments and formulations are described in
Tables 1 and 2.
Considering the total amount of solids in the dispersion before
spray drying, ﬁrst 10% EPA was  tested in different proportions of
X1 and X2. With these results, after characterizations, the best two
results were selected, and the amount of EPA was  increased to
20%. 10% of the total of liquid used to prepare the dispersions was
ethanol, to solubilize the EPA. The remainder was water, to disperse
the proportions of GA/MD. The EPA solution and the GA/MD disper-
sions were stirred separately for 20 min. Then the EPA solution was
added to the GA/MD dispersion, stirred for about 5 min, and spray
dried.
Yield of microparticle powder
The total powder obtained after spray drying was weighed and
the percentage over the initial amount of solids was  taken as the
yield microparticle powder.
Moisture content of spray-dried powders
The residual moisture of the EPA microparticles was measured
with an infrared analytical balance (Ohaus-MB 200, Pine Brook, NJ,
USA) on a 2.0 g sample at 105 ◦C for 30 min. Three replicates were
carried out, and calculated mean and standard deviation.
Morphology and particle size analysis
The morphology of the particles produced was  analyzed by
means of a scanning electron microscope (SEM, Shimadzu SS-550,
Tokyo, Japan) with Image Pro Plus software (Media Cybernetics,
Rockville, MD,  USA). The particles were coated with gold/palladium
under argon atmosphere and the SEM images were recorded. Their
size was  determined by measuring Feret’s diameter. More than
800 particles were measured and the particle size distribution was
estimated.
Loading efﬁciencyThe EPA was extracted from the microparticles using a portion of
puriﬁed water and dissolved in a 20% methanol ﬁnal solution. The
samples in 20% methanol were submitted to solid-phase extrac-
tion (SPE cartridge, Strata C18-E, Phenomenex) prior to analysis,
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Table 2
Details of formulations.
Sample Total dispersion (g) GA (g) MD (g) EPA (g) Water (g) Ethanol (g)
1 100 2.70 6.30 1.0 81.0 9.0
2  100 3.60 5.40 1.0 81.0 9.0
3  100 4.50 4.50 1.0 81.0 9.0
4  50 2.70 6.30 1.0 36.0 4.0
5  50 3.60 5.40 1.0 36.0 4.0
6  50 4.50 4.50 1.0 36.0 4.0
7  40 3.24 7.56 1.2 25.2 2.8
8  40 4.32 6.48 1.2 25.2 2.8
9  40 5.40 5.40 1.2 25.2 2.8
10  100 9.00 – 1.0 81.0 9.0
9.00
5.60
4.00
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12*  100 2.40 
13*  100 4.00 
ue to the presence of solid residues. The EPA was measured for
atechin and epicatechin contents, using a HPLC method proposed
nd validated previously (Klein et al., 2012, 2013). The HPLC system
onsisted of a Thermo HPLC equipped with pumps and an integral
egasser (Finnigan Surveyor LC Pump Plus), PDA spectrophoto-
etric detector module (Finnigan Surveyor PDA Plus Detector),
ontroller software (Chromquest), and autosampler (Finnigan Sur-
eyor Autosampler Plus) equipped with a 10 l loop for injection.
hromatographic separation was conducted using a Synergi POLAR
 RP 80A stainless-steel analytical column (250 mm × 4.6 mm,
 m),  and a C18 guard cartridge system (4.6 mm × 20 mm,  4 m)
Phenomenex®). The mobile phase was a gradient system of 0.05%
FA–water (phase A) and 0.05% TFA–acetonitrile:methanol (75:25,
 v−1) (phase B), previously degassed using an ultrasonic bath. Gra-
ient separation was performed at a ﬂow rate of 0.5 ml  min−1, and
he detection was performed at 280 nm.
hermal analysis
EPA, GA, MD,  microparticle formulations, and physical mix-
ures (PM) of the substances were analyzed by differential scanning
alorimetry (DSC) and thermogravimetric analysis (TGA) on a
alibrated Netzsch STA 409PG/4/G Luxx thermal analyzer (Selb,
ermany). Thermograms were recorded by placing accurately mea-
ured quantities of each sample in a platinum pot in analysis
tmosphere with constant ﬂow of nitrogen (N2) at 50 ml  min−1.
he samples were heated from ambient temperature to 500 ◦C at a
eating rate of 10 ◦C min−1.
PPH radical scavenging capacity
The DPPH radical scavenging capacity was determined accord-
ng to a method described previously (Chassot et al., 2011).
The free radical scavenging activities of semipuriﬁed extract
PA, the positive control Trolox, and formulations 1, 3, 12,
nd 13 were measured by using 2,2-diphenyl-1-picryl-hydrazyl
DPPH, Sigma). Solutions of EPA, Trolox® (6-hydroxy-2,5,7,8-
etramethylchroman-2-carboxylic acid, Sigma) and formulations
, 3, 12, and 13 at different concentrations were dissolved in
 ml  of methanol and then added to a methanolic solution of free
adical DPPH (1 mM,  375 l). The mixture was strongly shaken
nd maintained at room temperature for 30 min  in the darkness.
he absorbance of the resulting solution was read spectrophoto-
etrically (Shimadzu UV/vis PC-1650, Japan) at 517 nm against a
lank (2 mg  of butylated hydroxytoluene-BHT, dissolved in 4 ml  of
ethanol with 500 l of the free radical DPPH solution added). The 1.0 81.0 9.0
 2.0 80.0 10.0
 2.0 80.0 10.0
capability to scavenge the DPPH radical or to inhibit free radicals
was calculated using the following equation:
I% = (Ab − As)
Ab
× 10 (1)
where I% is the capability to scavenge the DPPH radical or to
inhibit free radicals, Ab is the absorbance of the control reaction
(containing all reagents except the test compounds), and As is
the absorbance of the test compound. The sample concentration
providing 50% inhibition (IC50), concentration required to inhibit
DPPH radical formation by 50%, was  calculated from the graph of
I% against sample concentration. Tests were carried out in tripli-
cate. Trolox® was used as positive control or standard. Data are
presented as IC50 (g ml−1).
In vitro drug release studies
In vitro dissolution assays of EPA from the microparticles were
carried out in triplicate on a Sotax® AT 7 Smart Apparatus (Manch-
ester, USA) using a 22.6 mm  ﬂow cell, with the microparticles
placed between layers of glass spheres. The release medium was
puriﬁed water (pH 6.5) at 37 ± 0.5 ◦C, and ﬂow at 8 ml  min−1. The
sink conditions were determined and maintained. For evaluation
of EPA release, 100.0 mg  of formulations 1 and 3, and 200.0 mg  of
formulations 12 and 13 were used. Samples were placed on the
ﬂow cell and at predetermined time intervals (5, 10, 15, 30, 45, and
60 min), 5 ml  samples of dissolution ﬂuid were collected and the
volume completed to 25 ml,  and the catechin and epicatechin con-
centrations were analyzed by HPLC (Klein et al., 2012). None of the
formulation components was  found to interfere with the analysis.
Model parameters
Five different kinetic models (zero-order, ﬁrst-order, Higuchi,
Korsmeyer–Peppas and Baker–Lonsdale model) were used to ﬁt the
experimental data obtained in the drug release experiments.
Q = k Zero-order equation (2)
Q = 1 − e−kt First-order equation (3)
Q = kt1/2 Higuchi’s equation (4)
Q = ktn Korsmeyer–Peppas (5)
3
2
[
1 −
(
1 − Qt
Q∞
)2/3]
− Qt
Q∞
= kt (6)
where Q is the fraction of drug released at time t and Q∞ at inﬁ-
nite time, k is the release rate constant, n is the diffusion release
exponent that could be used to characterize the different release
mechanism, n ≤ 0.43 (Fickian diffusion), 0.43 < n < 0.85 (anomalous
transport), and ≥0.85 (case II transport) (Costa and Lobo, 2001).
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Table  3
Details and results of microparticles powders characterizations experiments.
Sample AG:MD % Solids Yield (%) Moisture
(% ± SD)
Loading efﬁciency
(% ± SD)
Catechin Epicatechin
1 30:70 10 62.39 5.60 ± 0.14 99.15 ± 2.07 97.95 ± 8.70
2  40:60 10 57.62 7.44 ± 0.27 85.02 ± 0.10 89.02 ± 0.59
3  50:50 10 58.59 5.27 ± 0.39 87.14 ± 1.18 91.31 ± 8.09
4  30:70 20 45.88 6.10 ± 0.09 92.94 ± 1.58 89.62 ± 4.96
5  40:60 20 57.50 6.24 ± 1.19 81.53 ± 0.75 90.73 ± 6.57
6  50:50 20 55.70 6.00 ± 0.70 97.94 ± 0.58 108.35 ± 2.70
7  30:70 30 37.19 5.66 ± 0.25 88.36 ± 0.84 91.39 ± 0.33
8  40:60 30 36.66 5.26 ± 0.55 81.73 ± 1.04 90.66 ± 2.83
9  50:50 30 34.70 6.10 ± 0.52 81.55 ± 1.82 82.10 ± 10.15
10  100:0 10 42.12 6.03 ± 0.20 87.04 ± 0.97 89.22 ± 11.79
11  0:100 10 51.90 6.03 ± 0.11 84.05 ± 1.09 86.79 ± 3.14
12a 30:70 10 60.00 8.40 ± 0.50 95.61 ± 1.69 84.81 ± 7.39
13a 50:50 10 55.54 5.73 ± 0.15 96.34 ± 1.62 84.16 ± 10.56
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Table 4
Particle size of microparticles formulations.
Sample Particle size
(m) ± SD
Size interval (m)
1 4.22 ± 1.79 1.31–12.46
2  4.72 ± 1.98 1.64–14.45
3 4.92 ± 2.15 1.39–17.39
4  4.81 ± 2.53 1.05–18.20
5  4.97 ± 2.10 1.14–15.75
6  6.71 ± 3.41 1.03–20.48
7  4.74 ± 2.27 1.05–15.75
8  4.48 ± 2.16 1.35–16.48
9  7.51 ± 4.03 1.01–30.46
10  5.64 ± 2.37 1.85–15.50
11  5.78 ± 2.17 1.24–14.98
12  4.34 ± 1.97 1.36–13.67a EPA percentage increased to 20% in total solids.
D, standard deviation; AG:MD, proportion of arabic gum:maltodextrin.
inear regression was performed and the model parameters calcu-
ated.
tatistical analysis
All experiments were performed at least in triplicate. The data
ere compared by one-way analysis of variance (ANOVA) and
ukey post hoc test using the Statistica 8 software (StatSoft, Tulsa,
K, USA). A p-value <0.05 was considered statistically signiﬁcant in
ll cases.
esults and discussion
esults of microparticles powders characterizations experiments
The microparticle formulations, and the details and results of
he microparticle powder characterizations (yield, moisture, and
oading efﬁciency to catechin and epicatechin) are described in
able 3.
The ANOVA indicated p < 0.05 for the variable yield. Therefore,
t least one sample showed a yield different from the others, and
o determine which sample(s) differed we applied the test for mul-
iple comparisons. Samples with 10 and 20% solids gave equivalent
ields, which were higher than the samples with 30% solids.
For the variable catechin encapsulation content, no sample
howed a catechin encapsulation content signiﬁcantly different
rom the others (p > 0.05). The %GA and the percentage of solids
n each sample did not signiﬁcantly affect the catechin encapsu-
ation content. For the variable epicatechin encapsulation content,
he results were p > 0.05, so the conditions for epicatechin are the
ame as for catechin.
Therefore, we chose 10% of solids in dispersion the reference for
he production of microparticles, and the formulations with 30%
olids were excluded from subsequent characterizations. The 20%
olids was initially an option for the production of microparticles,
ut although the yield of the microparticles was equivalent to the
icroparticles produced with 10% solids, in practice the dispersion
s very viscous and difﬁcult to spray dry.
The 10% solids percentage was chosen to test the extreme
oncentration of %GA, in order to better characterize these formula-
ions (formulations with 30% and 50% of GA). We  increased the EPA
oncentration to 20% (samples 12 and 13) only in the formulations
hat provided the best results (samples 1 and 3).
According to the results of the initial characterization of pow-
ers of microparticles, we concluded that 10% solids is most suitable
oncentration for the production of microparticles, in the working13  4.67 ± 1.85 1.43–13.32
SD, standard deviation.
conditions. Formulations 1, 3, 12, and 13 obtained the best results
for the tests performed and were used in subsequent studies.
Particle size analysis and morphology
The size of the microparticles was  very similar in all formula-
tions (Table 4). Only samples 6 and 9 had a larger particle size,
probably due to the higher content of GA combined with the higher
percentage of solids in the initial dispersion. The microparticles,
with a mean diameter around 4.5 m,  indicated that the arrange-
ments of both polymers and EPA in the micrometric particles
containing the drug were homogeneously distributed, showed well
formed, small, spherical in shape microparticles, presence of sur-
face depression (or collapse) and absence of particles aggregates
and crystals (Sansone et al., 2011).
For the microparticle morphology analysis, SEM micrographs
were used. Fig. 1 shows the morphology of samples 1, 3, 12, and
13 and the formulations of the samples without EPA. These for-
mulations were chosen because they gave the best results in the
characterization tests, and were used for the dissolution tests.
All the samples displayed an absence of crystals and aggregates.
These results indicate a possible interaction and solubilization of
EPA in the GA:MD microparticles (Sansone et al., 2011). The pho-
tomicrographs of samples 12 and 13 showed small and well-formed
spherical microparticles, and those of samples 1 and 3 revealed
microparticles with a more irregular shape and the presence of par-
tially collapsed particles. These studies indicate that the amount
of EPA had a signiﬁcant inﬂuence on the microparticles, altering
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cig. 1. SEM photomicrographs of microparticles (2000×). 1–4: formulations of sam
ith  EPA.
he morphology, as observed by with chitosan microspheres for
ncapsulation of -lipoic acid (Weerakody et al., 2008).
hermal analysis
Thermal analysis may  provide information on the solid state
nd extract–polymer interactions as well as on physical stability
f materials after the technological process. Differential scanning
alorimetry (DSC) and thermogravimetric analysis (TGA) were per-
ormed to evaluate the stability of the microparticles after thermal
xidation (temperature increase) (Weerakody et al., 2008).
Overall, two thermal events were observed for EPA and for
A, MD,  microparticles, and the physical mixtures in the DSC
urves (Figs. 2–4). The ﬁrst endothermic event was between room, 3, 12, and 13, respectively without EPA; A–D: samples 1, 3, 12, and 13, respectively
temperature and 150 ◦C, depending on the sample, and corre-
sponded to loss of absorbed water. The difference of several ◦C
up or down can be related to the binding mode of water in dif-
ferent samples, characteristic of each substance, which required
more or less energy to release it. As observed by in previously study
(Borghetti et al., 2006), samples of quercetin from different suppli-
ers had different temperatures of water loss, caused by differences
in morphology and particle size. The second endothermic event
observed for all samples corresponds to the melting point, with pos-
sible degradation of these compounds due to the high temperatures
involved in this process (over 240 ◦C).
These results can be conﬁrmed by analysis of the TGA curve, in
which a mass loss can be observed at these temperatures, probably
related to degradation of these substances (Figs. 5–7).
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Fig. 3. DSC curves for microparticles for samples 1, 3, 12, and 13.
The DSC curves indicated an interaction between EPA and
A:MD in the microparticles, because in the second endothermic
vent there was a mixture of proﬁles of the individual substances.
Analyzing the data for TGA revealed two characteristic mass
osses, of EPA as well as GA, MD,  and microparticles. The ﬁrst mass
oss corresponds to water desorption, which began almost at room
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Fig. 4. DSC curves for physical mixtures (PM) 1, 3, 12, and 13.Fig. 6. TG curves of microparticles for samples 1, 3, 12, and 13.
temperature and continued up to 120 ◦C. This loss was around
5–12% of the total mass. The second loss corresponds to the melting
with degradation discussed above, and progressed to a structural
collapse.
The results for the TGA curves indicate that the proﬁle curves
of the microparticles are similar to the adjuvants used in microen-
capsulation process (GA and MD), including the mass losses. This
is probably due to the higher proportion of adjuvants compared to
EPA, which was present in a proportion of 10 or 20%.
DPPH radical scavenging capacity
The IC50 expresses the amount of EPA microparticles necessary
to scavenge 50% of free radicals present in the medium, and shows
the antioxidant capacity. Fig. 8 shows the results for the antioxidant
capacity of the semipuriﬁed extract EPA, the positive control Trolox,
and formulations 1, 3, 12, and 13.
It is expected that EPA will lose some antioxidant capacity
after the spray-drying process (Fu et al., 2011). As shown in Fig. 8,
samples 1, 3, and 12 showed smaller antioxidant capacities than
Trolox (positive control) and EPA. Only sample 13 demonstrated a
similar antioxidant capacity to the control and EPA. This suggests
that microparticles can protect the EPA from the effect of high
298 T. Klein et al. / Revista Brasileira de Far
1000
10
20
30
40
50
60
70
80
90
100
PM 1
PM 3
PM 12
PM 13
200
Temperature ºC
%
 m
as
s
 300 400 500
Fig. 7. TG curves for physical mixtures (PM) 1, 3, 12, and 13.
Trolox
0
2
4IC
50
 (µ
g 
m
-L
–
1 )
6
8
a a
c b,c
d
a,b10
12
EPA 1 3 12 13
Fig. 8. Antioxidant capacity of semipuriﬁed extract EPA, the positive control, Trolox,
and the formulations 1, 3, 12, and 13 (a–d: same letters indicate values with the same
statistical signiﬁcance).
0
0 5
Cat 1 Epicat 1
10 15 30 45 60
20
40
60
80
100
A 
C
Time (min)
Cu
m
ul
at
iiv
e 
re
le
as
e 
(%
)
0
0 5
Cat 12 Epicat 12
10 15 30 45 60
20
40
60
80
100
Time (min)
Cu
m
ul
at
iiv
e 
re
le
as
e 
(%
)
Fig. 9. Dissolution proﬁle of the markers catechin (Cat), and epicatechin (Epicat) from sam
(Klein et al., 2012).macognosia 25 (2015) 292–300
temperatures during the process (Fu et al., 2011; Sansone et al.,
2011). The antioxidant activity was maintained in epigallocatechin
gallate microparticles that were spray dried at temperatures
ranging from 95 to 130 ◦C (Fu et al., 2011). The microencapsulation
improved stability, preventing the loss of the quercetin antioxidant
capacity during 12 months of storage (Sansone et al., 2011).
This study demonstrated signiﬁcant retention of the antioxidant
capacity of EPA after the microparticle production.
In vitro dissolution tests
First, to evaluate the dissolution/release proﬁle of EPA from
microparticles, their solubility in the medium was assessed. The
solubility value of EPA was  0.92 mg  ml−1 in water. Then, the sink
conditions, which describe a dissolution system sufﬁciently dilute
so that the dissolution process is not impeded by saturation of the
solution, were evaluated. The dissolution proﬁles of EPA from the
microparticles are shown in Fig. 9.
All formulations evaluated in the dissolution test started the
release at the beginning of the test and showed complete dissolu-
tion within 60 min. Among the compounds tested, only sample 1
had a different proﬁle, releasing all the contents in the ﬁrst 15 min.
All formulations released the total content of EPA, suggesting that
no interactions occurred between the polymers and EPA that were
able to retain the active compounds in the polymeric mixture.
The microparticles dissolve through a process of erosion of the
matrix together with swelling (Aulton, 2007), with a large contact
area. It was expected that the microparticles would release the
active compounds more rapidly with immediate release, but this
was not observed. A plausible explanation for this release proﬁle
is that the fraction is microencapsulated, it has hygroscopic char-
acteristics and good solubility; however in aqueous dispersion it is
different, and may  tend to release more slowly (Klein et al., 2013).
In analyzing the results of the release proﬁle, different values of
n (release exponent), which characterizes the release mechanism,
were obtained. The n values and correlation coefﬁcients (r) of cate-
chin and epicatechin in the samples are summarized in Table 5.
For spherical shapes, the ranges of n values are: Fickian diffu-
sion (n ≤ 0.43), non-Fickian diffusion (0.43 < n < 0.85), and transport
mechanism type II (n > 0.85). Therefore, the microparticles of
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T. Klein et al. / Revista Brasileira de Farmacognosia 25 (2015) 292–300 299
Table  5
Catechin and epicatechin release exponent (n) values and correlation coefﬁcients (r) from dissolution proﬁles obtained by Korsmeyer–Peppas model (*) and by Baker–Lonsdale
model  (**).
Sample n* r* r**
Catechin Epicatechin Catechin Epicatechin Catechin Epicatechin
1 0.2316 0.3133 0.8812 0.9309 0.8167 0.8804
82 
29 
63 
s
t
l
l
1
w
t
r
b
r
a
c
m
a
u
a
a
0
i
t
w
c
m
t
C
t
g
t
f
f
T
s
d
s
p
C
A
d
d
s
J
w
t3  0.4853 0.5540 0.98
12  0.5290 0.5690 0.99
13  0.4828 0.5428 0.99
ample 1 showed release with an inﬂuence of Fickian diffusion. In
his context, the microparticles of sample 3 would show anoma-
ous behavior, with a greater inﬂuence of Fickian diffusion and
ess relaxation of the polymer chains. The microparticles of sample
2 would show Higuchi’s model proﬁle with anomalous behavior,
ith a greater inﬂuence of Fickian diffusion and less relaxation of
he polymer chains. The microparticles of sample 13 would show
elease proﬁle very close to the Higuchi model, and anomalous
ehavior, with a greater inﬂuence of Fickian diffusion and less
elaxation of the polymer chains (Aulton, 2007). However, it was
lso observed a biphasic behavior for the release of epicatechin and
atechin from samples 3, 12, and 13. Therefore, it was applied the
odel of Baker–Lonsdale, which describes the drug release from
 non-homogeneous spherical matrix by diffusion, and has been
tilized to analyze the results of drug release from microspheres
nd microcapsules. The correlation coefﬁcients (r) of epicatechin
nd catechin release from samples 3, 12, and 13 were higher than
.97 (Table 5), conﬁrming the diffusion is the main phenomenon
nvolved in the release of the active agents from the formulations.
The aqueous medium was chosen as a ﬁrst step in assessing
he release of markers in the dosage form, because freshly puriﬁed
ater lacks interfering attributes, i.e.,  has a pH close to neutral and
ontains no ions. For future studies, we intend to evaluate acidic
edia, simulating the environment of the gastric or the intestinal
ract (Klein et al., 2013).
onclusions
This study investigated the use of the spray-drying technique
o produce microparticles containing a semipuriﬁed extract of
uaraná (EPA). The study demonstrated the feasibility of producing
hese microparticles using gum arabic and maltodextrin polymers
or a one-step process using spray drying. The composition of each
ormulation inﬂuenced the physical and chemical characteristics.
he results of the in vitro dissolution test may  be related to the
tructure of each formulation of microparticles, which hinders the
elivery of the markers within 60 min. This spray-drying technique
hows great potential as an efﬁcient and economic process for the
roduction of EPA microparticles for drug delivery.
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